drugset / Trial / NCT02975297

Exenatide Once Weekly for Smoking Cessation

NCT02975297

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to identify a potential new treatment for smoking cessation.

Timeline

Start
2016-07
Primary completion
2020-01-03
Completion
2020-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2 mg Subcutaneous
Background Nicotine Unknown 21 mg Other

Indications

No indication recorded.